UPDATE: Strongbridge Biopharma To Receive Upfront Payment Of $145M And Tiered Royalties Related To Sales Of MACRILEN Through 2027; Novo Nordisk To Purchase 5.2M Ordinary Shares Of Stonebridge At $7/Share